Why it is worth using a single pill combination of perindopril and amlodipine? Review article

Article Sidebar

Requires Subscription PDF (Język Polski)


Published: Jun 30, 2024
DOI: https://doi.org/10.24292/01.MF.0224.14
Keywords:
perindopril, amlodipine, single pill combination, antihypertensive therapy

Main Article Content

Wioletta Dyrla
Klinika i Katedra Kardiologii, Nadciśnienia Tętniczego i Chorób Wewnętrznych, Wydział Lekarski, Warszawski Uniwersytet Medyczny; Mazowiecki Szpital Bródnowski w Warszawie
Marek Kuch
Klinika i Katedra Kardiologii, Nadciśnienia Tętniczego i Chorób Wewnętrznych, Wydział Lekarski, Warszawski Uniwersytet Medyczny; Mazowiecki Szpital Bródnowski w Warszawie

Abstract

Arterial hypertension is the most common disease of the cardiovascular system. For several years, guidelines have recommended starting hypertension therapy with a preparation consisting of two components. The recommended drug combinations in first-line therapy include an angiotensin-converting enzyme inhibitor and a dihydropyridine calcium channel blocker. The natural choice should be a drug composed of perindopril and amlodipine. Perindopril is an agent with proven antihypertensive effectiveness and unique pleiotropic properties, which results in reduction in cardiovascular events and improved patient prognosis. In turn, amlodipine, the most frequently used representative of calcium channel blockers with a long and strong effect. The combination of perindopril and amlodipine is an example of synergism of antihypertensive effect, pleiotropic properties, elimination of side effects and very good tolerance. All patients with hypertension, especially at high cardiovascular risk, atherosclerosis, coronary artery disease or metabolic disorders, will benefit from using SPC of these drugs.

Article Details

How to Cite
Dyrla, W., & Kuch, M. (2024). Why it is worth using a single pill combination of perindopril and amlodipine?. Medycyna Faktow (J EBM), 17(2(63), 269-275. https://doi.org/10.24292/01.MF.0224.14
Issue
Vol 17 No 2(63) (2024)
Section
Articles

Copyright © by Medical Education. All rights reserved.

References

1. Zasady postępowania w nadciśnieniu tętniczym – 2019 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tętniczego. Nadciśnienie Tętnicze w Praktyce. 2019; 5(1): 1-86.
2. Dinicolantonio JJ, Lavie CJ, O’Keefe JH. Not All Angiotensin-Converting Enzyme Inhibitors Are Equal: Focus on Ramipril and Perindopril. Postgrad Med. 2013; 125(4): 154-68. http://doi.org/10.3810/pgm.2013.07.2687.
3. Grajek S. Peryndopryl – formuła XXI wieku. A never ending story. Kardiologia Pol. 2023; 81(Supp. I, zeszyty edukacyjne).
4. Savarese G, Costanzo P, Cleland JGF, Vassallo E, Ruggiero D, Rosano G, Perrone-Filardi P. A Meta-Analysis Reporting Effects of Angiotensin- Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients Without Heart Failure. JACC. 2013; 61(2): 131-42. http://doi.org/10.1016/j.jacc.2012.10.011.
5. Van Vark L, Bertrand M, Akkerhuis KM, Brugts JJ, Fox K, Mourad JJ, Boersma E. Angiotensin-converting enzyme inhibitors reduce mortality in hypertension: a meta-analysis of randomized clinical trials of renin–angiotensin–aldosterone system inhibitors involving 158 998 patients. Eur Heart J. 2012; 33(16): 2088-97.
6. Tsoukas G, Anand S, Yang K. Perindopril is effective to significantly lower blood pressure in hypertensive patients untreated or uncontrolled on previous treatments: findings of the confidence trial. J Hypertens. 2010; 28: e469. http://doi.org/10.1097/01.hjh.0000379610.70883.95.
7. Svensson P, de Faire U, Sleight P, Yusuf S, Ostergren J. Comparative Effects of Ramipril on Ambulatory and Office Blood Pressures: A HOPE Substudy. Hypertension. 2001; 38(6): E28-32. http://doi.org/10.1161/hy1101.099502.
8. Mizuno Y, Yasue H, Yoshimura M, Fujii H, Yamamoto N, Nakayama M, Harada E, Sakamoto T, Nakamura S, Ito T, Shimasaki Y, Ogawa H, Saito Y, Nakao K. Effects of perindopril on aldosterone production in the failing human heart. Am J Cardiol. 2002; 89(10): 1197-200. https://doi.org/10.1016/s0002-9149(02)02304-4.
9. Morishita T, Tsutsui M, Shimokawa H, Tasaki H, Suda O, Kobayashi K, Horiuchi M, Okuda H, Tsuda Y, Yanagihara N, Nakashima Y. Long-term treatment with perindopril ameliorates dobutamine-induced myocardial ischemia in patients with coronary artery disease. Jpn J Pharmacol. 2002; 88(1): 100-7. https://doi.org/10.1254/jjp.88.100.
10. Cleland GJ, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Euro Heart J. 2006; 27(19): 2338-45.
11. Wytyczne ESC/ESH dotyczące postępowania w nadciśnieniu tętniczym (2018). Grupa Robocza Europejskiego Towarzystwa Kardiologicznego (ESC) i Europejskiego Towarzystwa Nadciśnienia Tętniczego (ESH) do spraw postępowania w nadciśnieniu tętniczym. Kardiol Pol. 2019; 77(2): 71-159. https://doi.org/10.5603/KP.2019.0018.
12. Tykarski A, Filipiak KJ, Rajzer M. Zalecenia ESH 2023 dotyczące postępowania w nadciśnieniu tętniczym. Próba komentarza na temat zmian w stosunku do zaleceń ESH/ESC 2018 i różnic w porównaniu z zaleceniami PTNT 2019. Nadciśnienie Tętnicze w Praktyce. 2023; 9(2): 45-84.
13. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension. J Hypertens. 2023; 41: 1874-2071.